SPRIM Pro
Indian Harbour Beach, Florida, 32937, United States
NCT Number: NCT06874361
This is a prospective, double-blind, sham-controlled, randomized, decentralized trial. This study aims to assess the safety and efficacy of the Mi-Helper transnasal cooling device for acute treatment of migraine in an at home setting.
Adults aged 18 years to 70 years old with a diagnosis of migraine (with or without aura) for at least one year will be recruited for this study.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Not applicable
Indian Harbour Beach, Florida, 32937, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The Mi-Helper device is a non-invasive, drug-free, novel therapy that uses a patented process of dry air flow across the nasal turbinates to induce a phase change (evaporation) that extracts energy (thermodynamics) causing local cooling which modulates nerves associated with pain and other symptoms of migraine. The device delivers a controlled pressure and flow of dry room temperature air along with a nebulized saline mist for added comfort and evaporative efficiency.
Time frame: 2 hours
Proportion of participants with a change in headache severity from mild/moderate/severe pain at baseline to no pain at 2 hours after treatment completion (if rescue medication was not used)
Time frame: 2 hours
Proportion of participants with a change from mild, moderate or severe symptom severity at baseline to none at 2 hours post treatment completion.
Time frame: 2-24 Hours
Proportion of participants with pain freedom with no administration of rescue medication and with no recurrence of a mild/moderate/severe headache
Time frame: 2 hours
Proportion of participants with a change in headache severity from severe or moderate pain at baseline to mild or no pain at 2 hours post treatment completion, or from mild pain at baseline to no pain no pain at 2 hours after treatment completion (if rescue medication was not used)
Time frame: 24 Hours
Measured by the Patient Global Impression of Change (PGIC), on which participants use a 7-point scale, where 1=very much improved to 7=very much worse. Scores of 1 or 2 will be considered successes.
Time frame: 2 Hours
Use of rescue medication before 2 hours post treatment completion.
Time frame: 0 Hours
Proportion of participants with a change in headache severity from mild/moderate/severe pain at baseline to no pain at 2 hours after treatment completion (if rescue medication was not used)
Time frame: 0 minutes
Proportion of participants with a change in headache severity from severe or moderate pain at baseline to mild or no pain at 0 hours post treatment completion, or from mild pain at baseline to no pain no pain at 0 hours after treatment completion (if rescue medication was not used)
Time frame: 2 - 48 Hours
Proportion of participants with pain freedom with no administration of rescue medication and with no recurrence of a mild/moderate/severe headache
Time frame: 0 minutes
Proportion of participants with a change from mild, moderate or severe symptom severity at baseline to none immediately post treatment completion.
Time frame: 0 hours
Proportion of participants with a change from severe or moderate symptom severity at baseline to the traditional 4-point Visual Rating Scalemild or none at 0 hours, or from mild symptom severity at baseline to none at 0 hours post treatment completion (based on the traditional 4-point Visual Rating Scale)
Time frame: 0 hours
Proportion of participants with a change from mild, moderate or severe symptom severity at baseline to none immediately post treatment completion (based on the traditional 4-point Visual Rating Scale)
Time frame: 0 Hours
Proportion of participants with a change from mild, moderate or severe symptom severity at baseline to none ( immediately post treatment completion.
Time frame: 0 hours
Proportion of participants with a change from mild, moderate or severe symptom severity at baseline to none immediately post treatment completion.
Time frame: 2 Hours
A reduction from mild, moderate or severe symptom severity at baseline to none at 2 hours post treatment completion.
Time frame: 2 Hours
Proportion of participants with a change from mild, moderate or severe symptom severity at baseline to none at 2 hours post treatment completion.
Time frame: 2 Hours
Proportion of participants with a change from mild, moderate or severe symptom severity at baseline to none at 2 hours post treatment completion.
Mi-Helper, Inc.
Industry
A Prospective, Double-blind, Sham-controlled, Randomized Clinical Trial to Assess the Safety and Efficacy of the Mi-Helper Device for Acute Treatment of Migraine in an At Home Setting.
Acronym: CALM3
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07015125
Brain Diseases, Central Nervous System Diseases
San Francisco, California, United States
View Trial DetailsNCT06695156
Brain Diseases, Central Nervous System Diseases
Washington D.C., District of Columbia, United States
View Trial DetailsNCT07071506
Brain Diseases, Central Nervous System Diseases
Aarhus C, Denmark
View Trial DetailsNCT03194555
Brain Diseases, Central Nervous System Diseases
North Miami, Florida, United States
View Trial Details